Novartis ends the VIBRANT-HD study and will not continue the program with Branaplam

Still the study brings us some very good news as the drug did reduce the levels of mutant (sick) huntingtin in the spinal fluid collected from the participants.  This is groundbreaking achievement as the drug is administered orally (through the mouth). Nevertheless, reducing huntingtin in a safe way seems to be a challenging process. 

In August the ongoing Phase II study with Branaplam was paused because some of the participants had negative side effects of the treatment. Since then Novartis has spent time to understand what happened and why it happened and today they announced that the program will be stopped.  The analysis of the data collected from the trial participants showed that there were several negative side effects.  Many, allthough not all, participants had injuries to nerve cells outside the brain and spinal cord, so-called peripheral neuropathy.  The levels of NfL (Neurofilament light) were increased and this is regarded as a sign of stress in the brain/nerve system.  A third negative sign that was found in the participants was an increase in fluid in parts of the brain. 

After having studied all the results carefully and considering options to change the dosing etc, the Novartis team decided that they will end the Branaplam program in HD.  This is because it’s seen to be too many negative things happening although the levels of sick huntingtin is lowered. 

-This time I was prepared for a negative result like this, says Astri Arnesen, president of EHA.  It’s of course sad and disappointing that Branaplam is not safe to take, nevertheless, it is a great positive thing coming out of this study:  a drug taken through the mouth did lower the levels of huntingtin.  That is a major step forward.  Luckily we have a lot of other promising projects ongoing so even with this «horse» out of the race – we still are very much into the race with several other good ones!